Epsilon Healthcare (ASX:EPN) Shares Slide: What's Behind the Drop?

Sonal Goyal

05 November 2026 01:55 PM AEDT

Epsilon Healthcare (ASX:EPN) Shares Slide: What's Behind the Drop?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Shares traded at A$0.020 during the 5 November 2026 session, down 13.04%.
Quarterly receipts were A$3.9 million for the September 2026 quarter, up 34% year on year.
Year-to-date Revenue is A$11.5 million, tracking at about A$16 million annualised.

Shares in Epsilon Healthcare Limited (ASX:EPN) fell during the Trading session on 5 November 2026, trading at A$0.020 and down 13.04% in the early afternoon. The S&P/ASX 200 was up 1.87%, near 9,000 points, over the same period. Epsilon operates a healthcare platform that includes a pharmacy business, Epsilon Pharmacy, and contract development and Manufacturing (CDMO) services. Its latest update is a quarterly activities report and Appendix 4C dated 30 October 2026.

Quarterly activities report released 30 October 2026

Epsilon reported quarterly receipts of A$3.9 million for the September 2026 quarter, up 34% year on year. Year-to-date revenue reached A$11.5 million, which the company said is tracking at A$16 million annualised and up 80%. Epsilon Pharmacy, established about 12 months earlier, is now delivering A$2.3 million in annualised revenue.

The company also pointed to new and expanded CDMO client contracts, growing international manufacturing and export opportunities, and digital platform use in its pharmacy business. It said Investment in expanded dosage form Diversification is expected to generate new dosage form revenue in the fourth quarter of 2026.

Sector context

At midday, the ASX Health Care sector was up 3.08%. Epsilon shares moved lower during the session, against that sector gain. The company's update is dated 30 October and is not linked to the 5 November share price move, so the reason for the day's fall is not stated in the announcement.

What to watch ahead

Attention will turn to the new dosage form revenue expected in the fourth quarter of 2026, the conversion of CDMO contracts into revenue and the next quarterly report, which will show whether receipts continue to grow.

Risks

Figures in the Quarterly Report are receipts and unaudited revenue rather than full-year earnings. The company is investing in new capacity and dosage forms, which carries cost and execution risk. Its pharmacy and CDMO revenue depends on customer Demand and contract renewals, and the stock is a small-cap with a low share price that can move sharply.

Final Word

Epsilon's latest quarter shows growth in receipts and a broader customer base. The share price fell sharply on the day, and investors will be watching the company's dosage form launches and contract progress in the coming quarters.

FAQs

Q: How much did Epsilon Healthcare receive in quarterly receipts?

A: The company reported quarterly receipts of A$3.9 million for the September 2026 quarter, up 34% year on year.

Q: What did Epsilon Healthcare shares do on 5 November 2026?

A: Shares traded at A$0.020 during the session, down 13.04%, while the S&P/ASX 200 was up 1.87%.

Q: What is Epsilon Pharmacy's annualised revenue?

A: The company said Epsilon Pharmacy is delivering A$2.3 million in annualised revenue.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.